Hsbc Holdings PLC Eagle Pharmaceuticals, Inc. Transaction History

Hsbc Holdings PLC

$168 Billion
Q3 2024

A detailed history of Hsbc Holdings PLC transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 11,396 shares of EGRX stock, worth $6,837. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,396

Previous 13,148 13.33%

Holding current value

$6,837

Previous $73,000 42.47%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.71 - $6.07 $6,499 - $10,634	-1,752 Reduced 13.33%	11,396 $42,000
Q2 2024 Aug 12, 2024	SELL	$3.34 - $5.6 $96 - $162	-29 Reduced 0.22%	13,148 $73,000
Q1 2024 May 15, 2024	BUY	$4.26 - $6.51 $5,022 - $7,675	1,179 Added 9.83%	13,177 $69,000
Q4 2023 Feb 12, 2024	BUY	$4.63 - $15.21 $55,550 - $182,489	11,998 New	11,998 $62,000
Q1 2021 May 14, 2021	SELL	$40.32 - $50.97 $342,115 - $432,480	-8,485 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$41.72 - $51.34 $20,317 - $25,002	-487 Reduced 5.43%	8,485 $395,000
Q3 2020 Nov 12, 2020	BUY	$37.02 - $51.28 $50,014 - $69,279	1,351 Added 17.73%	8,972 $381,000
Q2 2020 Aug 14, 2020	BUY	$43.24 - $55.02 $139,881 - $177,989	3,235 Added 73.76%	7,621 $366,000
Q1 2020 May 15, 2020	SELL	$34.37 - $60.07 $18,972 - $33,158	-552 Reduced 11.18%	4,386 $202,000
Q4 2019 Feb 14, 2020	SELL	$54.32 - $64.31 $297,836 - $352,611	-5,483 Reduced 52.61%	4,938 $297,000
Q3 2019 Nov 14, 2019	BUY	$53.25 - $59.98 $554,918 - $625,051	10,421 New	10,421 $590,000

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Account

Hsbc Holdings PLC Eagle Pharmaceuticals, Inc. Transaction History